{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tallman KA"],"funding":["U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"],"pagination":["41"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12827326"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Cholesterol is an essential structural component of all cells, and the sterol biosynthetic pathway provides critical precursors for essential homeostatic molecules. Sterol biosynthesis can be disrupted by pathogenic variants in genes, as well as commonly prescribed medications. These medications disrupt post-lanosterol biosynthesis at different steps. We attempted to classify their actions based on the biochemical signatures of sterol intermediates. Our previous screening of the NIH Clinical Compound library of >1800 compounds in clinical use suggested that over 30 medications can disrupt post-lanosterol biosynthesis. Of these, we selected 11 compounds for follow up in a human dermal fibroblast model. Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHC"],"journal":["Translational psychiatry"],"pubmed_title":["Post-lanosterol inhibition profile based classification of commonly used prescription medications."],"pmcid":["PMC12827326"],"funding_grant_id":["R56HD111119"],"pubmed_authors":["Anderson AC","Porter NA","Korade Z","Tallman KA","Mirnics K"],"additional_accession":[]},"is_claimable":false,"name":"Post-lanosterol inhibition profile based classification of commonly used prescription medications.","description":"Cholesterol is an essential structural component of all cells, and the sterol biosynthetic pathway provides critical precursors for essential homeostatic molecules. Sterol biosynthesis can be disrupted by pathogenic variants in genes, as well as commonly prescribed medications. These medications disrupt post-lanosterol biosynthesis at different steps. We attempted to classify their actions based on the biochemical signatures of sterol intermediates. Our previous screening of the NIH Clinical Compound library of >1800 compounds in clinical use suggested that over 30 medications can disrupt post-lanosterol biosynthesis. Of these, we selected 11 compounds for follow up in a human dermal fibroblast model. Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHC","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-06T20:17:59.071Z","creation":"2026-06-05T03:07:22.492Z"},"accession":"S-EPMC12827326","cross_references":{"pubmed":["41298375"],"doi":["10.1038/s41398-025-03785-7"]}}